A Phase 1 Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection (Anti LAG-3 Monoclonal Antibody) in Patients With Advanced/Metastatic Solid Tumor or Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Feb 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HLX 26 (Primary)
Indications Advanced breast cancer; Lymphoma; Rectal cancer; Solid tumours
Focus Adverse reactions
Sponsors Shanghai Henlius Biotech

Most Recent Events

21 Feb 2024 Status changed from active, no longer recruiting to completed.
16 Aug 2023 Status changed from recruiting to active, no longer recruiting.
06 Jun 2023 Results (n=12; As of December 22, 2022) assessing the safety of HLX26 in patients with advanced or metastatic solid tumors or lymphomas, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight